Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use
The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.
Drug Development
Synlogic and Caldera sign merger agreement
FDA regenerative medicine approvals show growing momentum
FDA grants fast track designation for HAYA Therapeutics’ HTX-001
Eisai and CORE Biomedicine agree on global licence for oncology pipeline
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
Argenx signs agreement to buy Forte Biosciences for $2.2bn
Biointron introduces RushData platform for AI-driven antibody discovery
